Crinetics Pharmaceuticals Inc (CRNX) — Cash Flow-to-Debt Ratio
Crinetics Pharmaceuticals Inc (CRNX) has a Cash Flow-to-Debt Ratio of -1.03x as of March 2026, meaning its operating cash flow of $-124.70 Million could theoretically repay -1% of its total liabilities ($120.68 Million) in one year. See Crinetics Pharmaceuticals Inc (CRNX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crinetics Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Crinetics Pharmaceuticals Inc across 10 annual periods. Also explore CRNX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Crinetics Pharmaceuticals Inc (2016–2025)
Year-by-year debt coverage analysis for Crinetics Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Crinetics Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.64x | $-377.92 Million | $143.41 Million | ▼ -28.0% |
| 2024 | -2.06x | $-225.97 Million | $109.79 Million | ▼ -19.1% |
| 2023 | -1.73x | $-166.31 Million | $96.25 Million | ▲ +46.2% |
| 2022 | -3.21x | $-115.20 Million | $35.85 Million | ▲ +30.8% |
| 2021 | -4.65x | $-88.59 Million | $19.07 Million | ▼ -8.8% |
| 2020 | -4.27x | $-62.03 Million | $14.53 Million | ▼ -21.9% |
| 2019 | -3.50x | $-46.38 Million | $13.24 Million | ▼ -101.5% |
| 2018 | -1.74x | $-19.46 Million | $11.19 Million | ▼ -461.7% |
| 2017 | -0.31x | $-9.48 Million | $30.62 Million | ▼ -6.5% |
| 2016 | -0.29x | $-5.47 Million | $18.80 Million | — |